Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3-6
Results highlight safety and promising clinical responses of R-3750, along with biomarker results demonstrating a differentiated immune mechanism